Biogen Inc’s Revenue by Segment (2016-2021)

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$49 per month*

60% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

Download

About

This statistic highlights Biogen Inc’s Revenue by Segment, split between Product, anti-CD20 therapeutic programs and other segments.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Biogen Inc’s Revenue by Segment from Q1 2016 onwards, split between Product, anti-CD20 therapeutic programs and other segments.

Product, net: Biogen’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer’s disease; and FUMADERM for the treatment of acute plaque psoriasis.

Revenue from anti-CD20 therapeutic programs: is referred to as RITUXAN and RITUXAN HYCELA collectively as RITUXAN.

Other Revenue: Revenue earned from collaborations and other relationships, technical development agreements, manufacturing services agreements, and royalty revenue on biosimilar products with Samsung Bioepis.

Biogen Inc’s Revenue by Segment

Revenue by Segment Q3 2020 Q2 2021 Q3 2021 Revenue contribution in Q3 2021
Product, Net $2.69 $2.24 $2.21 79%
Revenue from Anti-CD20 therapeutic programs $0.56 $0.44 $0.16 15%
Other Revenue $0.13 $0.10 $0.16 6%
Total $3.38 $2.78 $2.78 100%

Product, net: The revenue generated from the product net was $2.206 billion in Q3 2021. It showed a decline of around 18% on a  year-on-year basis from $2.690 billion in Q3 2020. This segment contributed 79% of the total revenue of Q3 2021.(All the figures are in billions, except percentages)

Revenue from Anti-CD20 therapeutic programs: This program has earned $0.415 billion in Q3 2021 which on a year-on-year basis showed a decline of 26% from $0.560 billion in Q3 2020. It contributes to 15% of the total revenue of Q3 2021.

Other revenues: Revenue from other sources such as royalties and collaborations have earned a total of $0.158 billion (or $ 518 million approximate) in Q3 2021, which is a 26% growth from $0.126 billion (or $126 million, approximate) in Q3 2020. This also constitutes 6% of the total revenue generated in Q3 2021.

About the Company  

Biogen Inc. was founded by several prominent biologists in Geneva-Walter Gilbert, Kenneth Murray, and Heinz Schaller. It is a Biotechnology pharmaceutical company, with its core growth areas being Immunology, Neuropathic pain, and Acute Neurology. It is solving problems with its products like TECFIDERA, and TYSABRI, treating several neuropathic diseases like relapsing MS and primary progressive MS and ADUHELM for treating Alzheimer’s disease and other potential anti-CD20 therapies with self-research and development and other collaboration agreements.

Did you like Biogen Inc’s Revenue by Segment statistic?

Access more such KPI (key performance indicator) data points, on thousands of US stocks, with Business Quant.

You can get started here.

Read more

Access Segment financials and KPI data on US stocks

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access only basic data
  • This statistic is not included The statistic that you're currently viewing, is not included in the Basic plan. Please subscribe to the Pro plan to access this statistic.
$0
per month
Start for Free

60% discount until May 31

Pro

For serious investing

  • This statistic is included Instant access to all the data and features on the Business Quant platform. This also includes access to the statistic that you're currently viewing.
  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access only basic data
  • This statistic is not included The statistic that you're currently viewing, is not included in the Basic plan. Please subscribe to the Pro plan to access this statistic.
$0
per month
Start for Free

60% discount on Annual plan

Pro

For serious investing

  • This statistic is included Instant access to all the data and features on the Business Quant platform. This also includes access to the statistic that you're currently viewing.
  • Granular KPI data Access segment financials, non-GAAP metrics and KPI data from presentations and filings. Examples include financials by segment / region / product category, AT&T's broadband subscriber trends, Tesla's deliveries by model and lots more.
  • Stock research tools Features include : Stock screener, Stock comparison, sector financials, stock warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Industry data & tools Access premium operating data on 40+ industries. Examples include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$49
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our features.
  • Custom built features Get tailored dashboards built specially for you , based on your set of requirements, to simplify your research workflow.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.